Subsequently, we treated the cells with CB-839 (1 μM), an inhibitor of GLS, and found that inhibition of GLS reduced proliferation, migration, and ATP production levels in endometrial cancer cells, while concurrent treatment with P4 further reduced these levels (Figure 7C–E). Here, GLS is linked to endometrial cancer.